Lyra Therapeutics IPO

4/30/2020

IPO

$56,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $47.0 million to $50.0 million to fund the clinical development and manufacturing and other pre-commercialization expenses for LYR-210 through completion of our Phase 3 clinical trial; approximately $4.0 million to $6.0 million to fund the development of LYR-220 through completion of our Phase 2 clinical trial; and the remainder, if any, to complete the transfer of our manufacturing process to a contract manufacturer, for platform development and other research and development expenses for our pipeline, and for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

480 Arsenal Way
Watertown, MA 02472
USA

Lyra Therapeutics (Nasdaq: LYRA) is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.